Zelebrudomide

Zelebrudomide (NX-2127) is an investigational new drug that is being evaluated by Nurix Therapeutics for the treatment of relapsed or refractory B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL)…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Zelebrudomide (NX-2127) is an investigational new drug that is being evaluated by Nurix Therapeutics for the treatment of relapsed or refractory B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and Waldenström macroglobulinemia (WM). It is an orally bioavailable proteolysis targeting chimera (PROTAC) designed to degrade Bruton's tyrosine kinase (BTK) along with the immunomodulatory proteins Ikaros (IKZF1) and Aiolos (IKZF3).

Text derived from https://en.wikipedia.org/w/index.php?oldid=1362344473 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.